Targeting the PD-1/PD-L1 axis in the treatment of lung cancer

Categoría del artículo: Research Article

Publicado en línea: 17 sept 2016

Páginas: 17 - 27

Recibido: 16 feb 2016

Aceptado: 16 feb 2016

DOI: https://doi.org/10.1515/fco-2015-0021

Palabras clave

NSCLC, PD-1, PD-L1, Nivolumab, Pembrolizumab

© 2016

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.